MyGlomCon
GlomCon Member Portal
Free · In‑App Purchases
Our goal is to enable our global network of nephrologists and nephropathologists to come together and define the future of glomerular disease care. GlomCon is a nonprofit, charitable 501c(3) organization, registered in the U.S.
Every GlomCon Lecture
GlomCon Seminars started in 2016 as virtual multidisciplinary seminars that included case discussions and lectures by world-renowned experts. Due to the outstanding learning experience provided by the exceptional faculty and speakers, GlomCon Seminars grew from a small virtual community of nephrologists in Boston to a weekly event with global participants from over 130 countries. This App provides access to the entire archive and more.
Professional Forum
A closed corner for healthcare professionals to exchange experience, and discuss the latest evidence, clinical trials, and diagnostic or treatment opportunities.
Courses and Fellowship
This App also provides access to KPCP and GlomCon Fellowship content to those who have successfully enrolled in those courses.
Ratings & Reviews
What’s New?
- Bug fixes and improvements.
The developer, Glomerular Disease Study and Trial Consortium, indicated that the app’s privacy practices may include handling of data as described below. For more information, see the developer’s privacy policy .
Data Not Linked to You
The following data may be collected but it is not linked to your identity:
- Contact Info
- Usage Data
- Diagnostics
Accessibility
The developer has not yet indicated which accessibility features this app supports. Learn More
Information
- Seller
- Glomerular Disease Study and Trial Consortium
- Size
- 78.6 MB
- Category
- Education
- Compatibility
Requires iOS 15.1 or later.
- iPhone
Requires iOS 15.1 or later. - iPad
Requires iPadOS 15.1 or later. - iPod touch
Requires iOS 15.1 or later.
- iPhone
- Languages
- English
- Age Rating
18+
- 18+
- Contains
Health or Wellness Topics
- In-App Purchases
Yes
- 2024 Kidney Pathology Cert $690.00
- Copyright
- © 2024 Glomerular Disease Study and Trial Consortium